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Midregional Pro-Adrenomedullin as a Predictor for
Therapeutic Response to Midodrine Hydrochloride in
Children With Postural Orthostatic Tachycardia Syndrome
Fengwen Zhang, MM,* Xueying Li, MM,† Todd Ochs, MD,‡ Li Chen, MM,* Ying Liao, MD,*
Chaoshu Tang, PHD,§ Hongfang Jin, PHD,* Junbao Du, MD*
Beijing, China; and Chicago, Illinois
Objectives This study was designed to explore the predictive value of the midregional fragment of pro-adrenomedullin (MR-
proADM) in assessing the therapeutic efficacy of midodrine hydrochloride for children with postural orthostatic
tachycardia syndrome (POTS).
Background Midodrine hydrochloride is an important therapeutic option for children with POTS. However, there has not been
any method to predict response to the drug. The MR-proADM is produced in equimolar amounts to adre-
nomedullin (ADM), and directly reflects levels of the rapidly degraded active peptide, ADM.
Methods Fifty-seven children with POTS were designated as the POTS group. Twenty healthy children served as the control
group. The children in the POTS group received midodrine hydrochloride treatment. The plasma concentration of
MR-proADM was measured, using a sandwich immunoluminometric assay. A receiver-operating characteristic
curve was used to explore the predictive value of MR-proADM.
Results Plasma levels of MR-proADM were significantly higher in children with POTS (75.0 [62.5 to 96.0] pg/ml) than in
the control group (58.5 [50.3 to 69.0] pg/ml). Plasma levels of MR-proADM in responders to midodrine hydro-
chloride was significantly higher than that of nonresponders (76.0 [66.0 to 91.0] pg/ml vs. 59.0 [54.0 to 65.5]
pg/ml, p  0.01]. A receiver-operating characteristic curve on the predictive value of MR-proADM showed that
the area under the curve was 0.879 with a 95% confidence interval of 0.761 to 0.997. Using a cutoff value for
MR-proADM of 61.5 pg/ml produced both high sensitivity (100%) and specificity (71.6%) in predicting the effi-
cacy of midodrine hydrochloride therapy for treating POTS.
Conclusions MR-proADM can help guide midodrine hydrochloride therapy in the management of POTS in children.
(J Am Coll Cardiol 2012;60:315–20) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.04.025Postural tachycardia syndrome (POTS) can be defined by
symptoms of orthostatic intolerance in association with
excessive tachycardia (1). Patients with POTS experience
difficulties with daily routines such as housework, shopping,
eating, and attending work or school. As a vasoconstrictor,
midodrine hydrochloride has been reported to improve
From the *Department of Pediatrics, Peking University First Hospital, Beijing,
China; †Department of Statistics, Peking University First Hospital, Beijing, China;
‡Northwestern University, Chicago, Illinois; §Department of Physiology and Patho-
physiology, Peking University Health Sciences Centre, Beijing, China; and the Key
Laboratory of Molecular Cardiology, Ministry of Education, Beijing, China. This
work was supported by Major Basic Research Project of China (2011CB503904,
2012CB517806), National Twelfth Five-Year Plan for Science & Technology
Support (2012BA103B03), Beijing Science and Technology Project, China
(D10100050010059), and the National Natural Science Foundation of China
(81121061). The authors have reported they have no relationships relevant to the
contents of this paper to disclose.Manuscript received November 30, 2011; revised manuscript received March 21,
2012, accepted April 2, 2012.symptoms and suppress standing heart rate. However, a
response rate when treated with midodrine hydrochloride
was only 68.4% (2). There has not been any useful predictor
for the proper use of this drug.
See page 321
Adrenomedullin (ADM) is a circulating 52-amino acid
vasopeptide, which has immune modulating, metabolic, and
vascular actions (3). It is a potent vasodilator with antimi-
togenic, natriuretic, and diuretic effects. Unfortunately,
quantifying it is almost impossible, because of its short half
life, its binding to complement factor H in the serum, and
its tendency to adhere nonspecifically to the cellular surface
(4,5). Recently, a more stable midregional fragment of
pro-adrenomedullin (MR-proADM), comprising amino
acids 45-92 of pre-proADM, has been identified in plasma.
This peptide is produced in equimolar amounts to ADM,
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of the rapidly degraded active
peptide ADM (6,7). Thus, we
presumed that children with
POTS, who had abnormal pe-
ripheral vascular resistance, might
have better response to midodrine
hydrochloride. The aim of the study
was to investigate the level of plasma
MR-proADM in children with
POTS and determine whether it
could be a reliable predictor for a
therapeutic response to midodrine
hydrochloride.
Methods
Subjects. The patient group consisted of 57 patients age
1 3 years with POTS. Twenty healthy children age 10
years served as controls. Our study referred to the
ollowing criteria to define POTS (8–10): 1) a child has a
ormal heart rate when supine and no evidence of any
ardiovascular diseases; 2) after standing up or getting up, a
hild has 3 of the following symptoms: dizziness, chest
istress, chest pain, headache, palpitation, pale face, amau-
osis, fatigue, discomfort, or syncope; 3) these symptoms
hould be relieved or diminished by recumbence, and the
ymptoms should occur repeatedly for 1 month; 4) in
ddition to the symptoms of orthostatic intolerance, POTS
s diagnosed with the quantitative sign of a heart rate
ncrease of 30 beats/min or greater or a heart rate of 120
eats/min within the first 10 min after standing during
ead-up test (HUT) or head-up tilt test (HUTT); simul-
aneously, the decrease of blood pressure should be 20/10
m Hg; and 5) children with other diseases that cause
ymptoms of autonomic nervous system (such as anemia,
rrhythmia, hypertension, or endocrine disorders) as well as
ardiogenic or neurogenic diseases that would induce syn-
ope were excluded. This study was approved by the ethics
ommittee of Peking University First Hospital, and all
articipants’ guardians were fully informed of the purpose
nd methods of the study.
rotocol for HUT or HUTT. The protocol for HUT or
UTT (11,12) is as follows. Drugs that could influence
ormal autonomic nervous system activity were avoided for
3 days before the test. The tests were performed in a quiet,
oftly lit, and temperature-controlled room equipped with
edical resuscitation facilities. Electrocardiograms and
lood pressure of subjects were continuously monitored by a
ash 2000 Multi-Lead Physiological Monitor (General
lectric, Schenectady, New York). For HUT, subjects stood
p after a 10-min rest. If a positive response (as defined in
he criteria for POTS) appeared within 10 min after
tanding, the test would be discontinued and a diagnosis of
OTS would be made. If changes in heart rate and blood
Abbreviations
and Acronyms
ADM  adrenomedullin
AUC  area under curve
HUT  head-up test
HUTT  head-up tilt test
MR-proADM  midregional
fragment of
pro-adrenomedullin
POTS  orthostatic
tachycardia syndrome
ROC  receiver-operating
characteristicressure were in normal ranges during HUT, subjects wouldndergo the HUTT, which consisted of placing subjects on an
lectrically motorized tilt table with a footboard and tilting it at
n angle of 60° after a 10-min rest period in a supine position.
he HUTT would be terminated when a positive response
ppeared, or when subjects completed the test, after being
ilted for 45 min with a negative result. Positive responses in
UTT have been defined by previous studies.
easurement of MR-proADM content in plasma. Pa-
ients were kept in supine position, and blood was drawn by
enipuncture, after an overnight fast, and was collected in a
ube containing ethylenediaminetetra-acetic acid and apro-
inin. The blood was centrifuged at 1600g for 15 min at
°C, and the plasma was collected. Plasma was kept at
80°C until assayed. The MR-proADM was measured in
sandwich immunoluminometric assay (Phoenix Pharma-
euticals, Burlingame, California). The assay employs 2
olyclonal rabbit antibodies to MR-proADM (amino acids
5-92), and has an analytical detection limit of 10 pg/ml.
rotocol of follow-up. Forty-four children in the POTS
roup, who received midodrine hydrochloride at 2.5 mg per
ay (2) for therapy, were followed up in a clinic at 3 months.
he number and frequency of symptoms, for every patient,
ere recorded to evaluate the drug’s therapeutic effect. Also,
he HUT was repeated. A placebo was not used in the study,
nd concomitant therapies (salt, volume, and exercise) were
eld constant. In drug intervention, 13 of 57 cases were not
iven midodrine treatment because of contraindications
ncluding allergy, bradycardia, and hypertension, and poor
edication compliance. Among them, 3 received meto-
rolol. The remaining 10 received oral saline therapy (oral
ehydration salts: NaCL 1.75 g, NaHCO3 1.25 g, KCL
0.75 g, glucose 10 g), 500 ml daily. They were not included
in our follow-up study.
Criteria for evaluating therapeutic effects. Symptom
scoring was utilized to evaluate therapeutic effect of mido-
drine hydrochloride (13). The scoring was based on the
typical symptoms of orthostatic intolerance, including syn-
cope, dizziness or light-headedness, chest tightness, nausea,
palpitation, and headache. A numerical value for each
symptom was determined by its frequency, as shown in
Table 1. For a participant, he or she might have 1 or more
symptoms of orthostatic intolerance. Each symptom had a
score according to its frequency. The total score for this
participant was the sum of all the scores derived from his or
her symptoms. The symptom scoring was done for every
participant both at the beginning and after 3 months of
Standard of Symptom Scoringfor Orthostatic IntoleranceTable 1 ta dard of Symptom Scoringfor Orthostatic Intolerance
Score Frequency of Orthostatic Intolerance Symptoms
0 Never
1 Once per month
2 Twice to 4 times per month
3 Twice to 7 times per week4 More frequent than once per day
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to the symptom queries, and parents provided the necessary
information when needed. The scores were taken at clinic
visits. The therapy was determined to be effective, when the
symptom scores decreased by at least 2.
Statistical methods. Statistical analysis was completed by
SPSS software version 13.0 (SPSS, Chicago, Illinois).
Measurement data were presented as mean  SD. Com-
parisons of age, height, body weight, supine systolic blood
pressure, supine diastolic blood pressure, supine heart rate,
and MR-proADM between the POTS group and the
control group were performed using the independent Stu-
dent t test. Comparisons of sex (male/female ratio) between
the POTS group and the control group were performed by
the chi-square test. Plasma MR-proADM values were
expressed as medians and quartiles, and comparisons be-
tween the POTS group and the control group were made by
the Mann-Whitney U test. Symptom score and delta heart
rate were compared by the paired t test, but plasma
MR-proADM level was compared by the Mann-Whitney
U test before and after treatment. A value of p  0.05 was
considered significant. A receiver-operating characteristic
(ROC) curve was utilized to evaluate the predictive value of
MR-proADM in assessing the therapeutic effect of mido-
drine hydrochloride. The area under curve (AUC) indicated
the predictive value of MR-proADM. That the 95% con-
fidence interval (CI) of AUC did not contain 0.5 or a
p value 0.05 confirmed that MR-proADM was a reliable
predictor of the therapeutic effect of midodrine hydrochlo-
ride in treating children with POTS. An AUC from 0.5 to
0.7 means a low predictive value; AUC from 0.7 to 0.9
means a moderate predictive value; and AUC 0.9 means a
high predictive value (14). Optimal cutoff value was deter-
mined by the maximum of Youden index, which is defined
as sensitivity plus specificity minus 1, where sensitivity and
specificity were calculated as proportions (15).
Results
Fifty-seven patients in the POTS group and 20 children in
the control group were enrolled in our study. The general
Baseline Characteristics of Study ParticipantsTable 2 Baseline Characteristics of Study Participants
Characteristics Control Group POTS Group p Value
Cases, n 20 57 —
Male/female 8/12 29/28 NS
Age, yrs 10.1 3.1 11.5 2.6 NS
Height, cm 144.6 14.5 149.4 14.9 NS
Body weight, kg 36.7 11.6 41.0 13.4 NS
Supine systolic BP, mm Hg 99.5 8.4 102.5 9.1 NS
Supine diastolic BP, mm Hg 62.9 6.7 62.0 9.1 NS
Supine heart rate, beats/min 76.7 6.7 76.4 10.3 NS
MR-proADM, pg/ml 58.5 (50.3–69.0) 75.0 (62.5–96.0) 0.01
Values are n, mean  SD, or median (interquartile range).
BP  blood pressure; MR-proADM  midregional fragment of pro-adrenomedullin; NS 
not significant; POTS  postural orthostatic tachycardia syndrome.characteristics including age, sex ratio, height, body weight,
supine blood pressure, and heart rate are shown in Table 2.
The plasma concentration of MR-proADM was signifi-
cantly higher in the POTS group than in the control group
(Table 2).
In the POTS group, 44 patients received midodrine
hydrochloride (2.5 mg/day, once daily). All of the 44
patients were rescored, and HUT was performed again,
after 3 months. Both their symptom scores and their
tachycardia during HUT were decreased significantly, when
compared with both before treatment (Table 3).
In the 44 patients with POTS, who received midodrine
hydrochloride for therapy, 27 patients were classified as
responders, with their symptom scores decreased by at least
2. The pre-treatment data, such as symptom scores and
changes in heart rates during HUT, did not differ between
the 27 midodrine hydrochloride responders and 17 nonre-
sponders. (Table 4).
The results showed that midodrine hydrochloride respond-
ers had higher plasma levels of MR-proADM than the
nonresponders, and the difference was significant (p  0.05)
(Table 4 and Fig. 1). The ROC curve (Fig. 2) of plasma
MR-proADM, for predicting the therapeutic effect of
midodrine hydrochloride, showed that AUC was 0.879
(95% CI: 0.761 to 0.997; p  0.01). Using a cutoff value for
MR-proADM of 61.5 pg/ml yielded both high sensitivity
(100%) and specificity (71.6%) in predicting the effect of
midodrine hydrochloride for treating POTS (Fig. 2).
Discussion
Plasma MR-proADM content in children with POTS.
In our study, we found a significant increase in MR-
proADM in the plasma of POTS children as compared
with those in healthy controls. However, the mechanism
responsible for the increased plasma level of MR-proADM
in children with POTS is unknown. Examining flow-
mediated vasodilation by color Doppler vascular ultrasonog-
raphy is a noninvasive method to evaluate the function of
vascular endothelium. A previous study by our group dis-
covered that children with POTS had greater flow-
mediated vasodilation than healthy children (16), indicating
that some children with POTS might have a disturbed
endothelial function. Adrenomedullin is secreted mainly by
vascular endothelial cells and is widely distributed in various
Comparisons of SymptomScores, Changes of Heart Rate in POTShildren Treated by Midodrine Hydrochloride
Table 3
C mparisons of Symptom
Scores, Changes of Heart Rate in POTS
Children Treated by Midodrine Hydrochloride
Treatment n Symptom Score Delta HR,* beats/min
Pre-treatment 44 5.6 2.6 37.7 7.9
Post-treatment 44 2.9 2.7 32.4 13.1
p Value — 0.001 0.016
Values are mean  SD. *Delta heart rate (HR) is the increased heart rate during head-up test.
POTS  postural orthostatic tachycardia syndrome.organs and tissues, including the adrenal medulla, myocar-
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precursor peptide (pre-proADM) by post-translational pro-
cessing. During the processing of pre-proADM, MR-
proADM is produced in equimolar amounts to ADM. This
peptide is relatively stable, thereby making it a surrogate
for plasma levels of ADM (7). We speculated that the
higher plasma levels of ADM and even MR-proADM
might be associated with the disturbed endothelial function
of children with POTS. Further studies concerning the
mechanisms for the increased plasma level of MR-proADM,
however, are still needed.
ADM pharmacology. The vasodilatory impact of ADM in
periphery arteries seems clear. However, the central effects
of ADM are not fully understood. The results of previous
studies indicated that centrally administered ADM (13-52)
could increase sympathetic nervous system activity, consis-
tent with tachycardia, but not necessarily vasodilation
(18,19), which enriched the pathophysiology of POTS and
explained the clinical symptoms to some extent, especially
the increased heart rate during the HUT.
Comparisons of Symptom Scores, Changes of Heart Rate, and MR-Between POTS Children With Different R p ns to Midodri e HydTable 4 C mpariso s of Symptom Scores, Changes f Heart aBetween POTS Children With Different Response to M
Subjects n
Pre-Treatment Symptom
Score
Pre-Treatment Delta HR,*
beats/min
Responders 27 5.2 2.7 36.8 7.6
Nonresponders 17 6.2 2.3 39.2 8.3
p Value — 0.05 0.05
Values are mean  SD. *Delta heart rate (HR) is the increased heart rates during head-up test.
Abbreviations as in Table 2.
Figure 1
Plasma proADM Values in Controls,
Responders, Nonresponders, and Those
Who Could Not Take Treatment
On the transversal axis, 1 stands for control subjects, 2 stands for respond-
ers, 3 stands for nonresponders, and 4 stands for 13 patients who could not
take treatment. proADM  pro-adrenomedullin.Importance of predicting therapeutic response to mido-
drine hydrochloride for children with POTS. Children
with POTS often have symptoms of orthostatic intolerance,
such as syncope, dizziness, chest distress, chest pain, head-
ache, palpitation, fatigue, and so on, and have a much
higher incidence of syncope compared with adults (8,9).
Additionally, the recurrent symptoms usually create physical
and psychological stresses in children’s daily lives, at home
and at school. Therefore, an effective treatment, to improve
symptoms, is necessary for the children with POTS. Gor-
don et al. (20) reported that treatment with midodrine
hydrochloride decreased tachycardia, during HUT, in 20
POTS patients. Hoeldtke et al. (21) discovered in 9 POTS
patients, the tachycardia during HUT could be suppressed,
1 h after taking midodrine hydrochloride (21). In our
present study, 44 children with POTS treated by midodrine
Figure 2 ROC Curve of Value Plasma Levels of MR-proADM
The receiver-operating characteristic (ROC) curve of the value plasma levels of
midregional fragment of pro-adrenomedullin (MR-proADM) for predicting the
therapeutic effect of midodrine hydrochloride in terms of symptom scoring. The
longitudinal axis represents sensitivity to predict the effectiveness of midodrine
hydrochloride therapy. The transversal axis represents the false positive rate
(1-specificity) of the prediction. The 45° green line of the graph stands for ref-
erence line, representing sensitivity being equal to false positive rate (e.g.,
does not have the predictive value completely). The blue curve is farther from
the reference line and nearer the upper left corner of the graph. Area under the
curve was 0.879 (95% confidence interval: 0.761 to 0.997; p  0.01).
Moridend MR-proADM
ine Hydrochloride
ost-Treatment Symptom
Score
Post-Treatment Delta HR,*
beats/min
MR-proADM,
pg/ml
1.3 1.3 32.6 14.8 76.0 (66.0–91.0)
5.5 2.4 32.2 10.4 59.0 (54.0–65.5)
0.01 0.05 0.01proADrochlte, a
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July 24, 2012:315–20 Postural Orthostatic Tachycardia Syndromehydrochloride were followed up for 3 months, and 27 of 44
children were responders (61.4%). Therefore, further look-
ing for a predictor of the effectiveness of midodrine hydro-
chloride for children with POTS, based on the complicated
pathophysiology of the disease including abnormal vascular
regulation, is of great importance for the individual thera-
peutic strategy.
Possible implications of MR-proADM in POTS. When
we analyzed the pre-treatment data, such as symptom scores
and heart rate changes during HUT, we found that they did
not differ between the responders and nonresponders before
the treatment. The pre-treatment symptom score and delta
heart rate were 5.2 2.7 beats/min and 36.8 7.6 beats/min
for responders and 6.2  2.3 beats/min and 39.2  8.3
beats/min for nonresponders. However, MR-proADM
plasma levels were significantly higher in patients who had a
response to midodrine hydrochloride than in nonresponders.
MR-proADM is produced in equimolar amounts to ADM,
which has peripheral vasorelaxing effects (6,22,23). Midodrine
hydrochloride, an -adrenoceptor agonist, is able to facilitate
he vasoconstriction (24). That explains why the patients
ith higher plasma levels of MR-proADM had better
esponses to midodrine hydrochloride. However, further
tudies are needed to examine the mechanisms responsible
or the better responses to midodrine hydrochloride in
atients with higher plasma levels of MR-proADM, con-
idering both the central and peripheral effects of ADM.
To examine the possible predictive value of plasma levels
f MR-proADM for the effectiveness of midodrine hydro-
hloride, we used ROC analysis and showed that plasma
evels of MR-proADM had both high sensitivity (100%)
nd specificity (71.6%) in predicting the efficacy of mido-
rine hydrochloride for treating POTS. It revealed that
hen the plasma level of MR-proADM was higher than
1.5 pg/ml, the efficacy rate was nearly 100%. Therefore,
he plasma level of MR-proADM can be taken as one of the
eference indices in choosing medication for children with
OTS.
There may be several different mechanisms for POTS,
ncluding increased orthostatic splanchnic and peripheral
ooling of blood, low blood volume, excessive orthostatic
lasma loss from vessels, altered plasma renin activity/
ldosterone ratios, and altered adrenergic receptor sensitiv-
ty (25–29). That may be the reason why not all the POTS
hildren are responsive to the same medication.
tudy limitations. In the present study, the improvement
f delta heart rate from supine to standing positions are not
linically meaningful after treatment with the drug although
he symptoms were improved significantly. Because of the
hort period of follow-up and relatively small number of
atients, further studies including a clinical trial of different
rug therapies is needed to increase treatment efficacy for
hildren diagnosed with POTS. A dynamic monitoring of
he plasma concentrations of MR-proADM at different
ime points and further exploring the pathophysiology of
OTS, including the central effect of ADM, is of greatmportance. Additionally, 13 children could not take mido-
rine hydrochloride because of their contraindication, and
hat was also considered to be the limitation of the study.
onclusions
he results of the study demonstrated that midodrine
ydrochloride could improve the symptom score of pediatric
OTS cases. But the improvement of heart rate changes
rom supine to standing positions are insufficient after
reatment with the drug. More important, however, the
resent investigation provided an assessment of the possible
ole of ADM as a vasoactive agent in pediatric patients with
OTS and suggested that MR-proADM could help guide
idodrine hydrochloride therapy in the management of
OTS in children.
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